BCL2 and acute myeloid leukemia: Further, dual inhibition of BCL-2 and MCL-1 synergistically enhanced apoptosis in AML cells, promoting initiation of clinical trials with drug candidates such as AMG176, AZD5991, or S64315 [43, 57, 70-72].